- Home
- ATEC vs VRDN Comparison
ATEC vs VRDN Comparison
Compare ATEC & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATEC | VRDN |
|---|---|---|
| Founded | 1990 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.7B |
| IPO Year | 2006 | N/A |
Fundamental Metrics
Financial Performance| Metric | ATEC | VRDN |
|---|---|---|
| Price | $20.70 | $32.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 12 |
| Target Price | $22.00 | ★ $39.73 |
| AVG Volume (30 Days) | ★ 2.1M | 1.7M |
| Earning Date | 10-30-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $728,020,000.00 | $70,789,000.00 |
| Revenue This Year | $26.83 | $26,477.48 |
| Revenue Next Year | $16.61 | $6.23 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 27.11 | ★ 23340.07 |
| 52 Week Low | $8.70 | $9.90 |
| 52 Week High | $22.66 | $34.04 |
Technical Indicators
Market Signals| Indicator | ATEC | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 56.91 | 60.60 |
| Support Level | $19.33 | $31.20 |
| Resistance Level | $21.42 | $33.52 |
| Average True Range (ATR) | 0.66 | 1.25 |
| MACD | -0.21 | -0.30 |
| Stochastic Oscillator | 59.05 | 51.76 |
Price Performance
Historical ComparisonAbout ATEC Alphatec Holdings Inc.
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).